These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 31902123)

  • 1. Safety outcomes of apixaban in patients with nonvalvular atrial fibrillation and severe renal impairment.
    Jones MJ; Eudaley ST; Moye RA; Hodge TA; Nesbit RM; Franks AS
    J Thromb Thrombolysis; 2020 Aug; 50(2):330-336. PubMed ID: 31902123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reprint of: Efficacy and safety of apixaban compared to warfarin for nonvalvular atrial fibrillation in end-stage renal disease on hemodialysis.
    Moore M; Vizcaino K; Ewing JA; St Ville M
    J Am Pharm Assoc (2003); 2024; 64(4S):102160. PubMed ID: 39152982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary stroke prevention with apixaban in nonvalvular atrial fibrillation: A subgroup analysis of the STANDARD study.
    Yasaka M; Umeyama M; Kataoka H; Inoue H
    J Stroke Cerebrovasc Dis; 2020 Sep; 29(9):105034. PubMed ID: 32807446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
    Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
    Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter prospective cohort study to investigate the effectiveness and safety of apixaban in Japanese elderly atrial fibrillation patients (J-ELD AF Registry).
    Okumura K; Yamashita T; Suzuki S; Akao M;
    Clin Cardiol; 2020 Mar; 43(3):251-259. PubMed ID: 31737921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States.
    Siontis KC; Zhang X; Eckard A; Bhave N; Schaubel DE; He K; Tilea A; Stack AG; Balkrishnan R; Yao X; Noseworthy PA; Shah ND; Saran R; Nallamothu BK
    Circulation; 2018 Oct; 138(15):1519-1529. PubMed ID: 29954737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
    Villines TC; Ahmad A; Petrini M; Tang W; Evans A; Rush T; Thompson D; Oh K; Schwartzman E
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):80-90. PubMed ID: 30500885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study.
    Verdecchia P; D'Onofrio A; Russo V; Fedele F; Adamo F; Benedetti G; Ferrante F; Lodigiani C; Paciullo F; Aita A; Bartolini C; Molini MG; Di Lenarda A; Mazzone C; Scotti L; Lanati EP; Iorio A
    J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):66-73. PubMed ID: 30540644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
    Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
    Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation.
    Mavrakanas TA; Garlo K; Charytan DM
    Clin J Am Soc Nephrol; 2020 Aug; 15(8):1146-1154. PubMed ID: 32444398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Sood NA; Bunz TJ; Coleman CI
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
    Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
    Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Off-Label Reduced Dose Apixaban in Older Adults With Atrial Fibrillation and Associated Outcomes.
    Campbell AM; Pae E; Lee E; Jacisin T; Price A; DeAngelo J
    Ann Pharmacother; 2024 Jun; 58(6):572-580. PubMed ID: 37712551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of Apixaban-Treated Patients, Evaluation of the Dose Prescribed, and the Persistence of Treatment: A Cohort Study in Catalonia.
    Gomez-Lumbreras A; Cortes J; Giner-Soriano M; Quijada-Manuitt MA; Morros R
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):494-501. PubMed ID: 29792125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease.
    Schafer JH; Casey AL; Dupre KA; Staubes BA
    Ann Pharmacother; 2018 Nov; 52(11):1078-1084. PubMed ID: 29871510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Low and Full Dose Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Renal Dysfunction (from a National Registry).
    Gurevitz C; Giladi E; Barsheshet A; Klempfner R; Goldenberg I; Kornowski R; Elis A
    Am J Cardiol; 2021 Nov; 159():87-93. PubMed ID: 34503821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
    Yao X; Shah ND; Sangaralingham LR; Gersh BJ; Noseworthy PA
    J Am Coll Cardiol; 2017 Jun; 69(23):2779-2790. PubMed ID: 28595692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
    Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
    Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
    Bahit MC; Lopes RD; Wojdyla DM; Held C; Hanna M; Vinereanu D; Hylek EM; Verheugt F; Goto S; Alexander JH; Wallentin L; Granger CB
    Heart; 2017 Apr; 103(8):623-628. PubMed ID: 27798052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.